Podcasts about Clinical research

Most clinical research treats patients like data points. What gets lost when researchers stop listening to the people they study, and what does it cost the science itself? Niharika Singh is a biomedical engineer and pre-medical student with research experience at Genentech, Abbott, AstraZeneca, and the Keck School of Medicine, and a global ambassador with the United Nations SURGhub. She discusses the KevinMD article "Patient involvement transforms modern clinical research." You will hear the difference between treating a patient as a data set, engaging them as a collaborator, and inviting their emotional and lived experience into the study design. She walks through the Tiger Project hernia training across India and Ghana, what medical device design verification taught her about surgical research, and why AI in medicine is making patient voice harder to hear. You will hear a research methodology that treats the patient's voice as data worth collecting, and a case for defending human connection as AI changes how medicine is practiced. Partner with me on the KevinMD platform. With over three million monthly readers and half a million social media followers, I give you direct access to the doctors and patients who matter most. Whether you need a sponsored article, email campaign, video interview, or a spot right here on the podcast, I offer the trusted space your brand deserves to be heard. Let's work together to tell your story. PARTNER WITH KEVINMD → https://kevinmd.com/influencer SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

In this episode of ACRO's GCP, Tinaya Gray (Executive Director, Site Engagement & PACE at ICON plc), Jan Hewett (SVP, FDA Regulatory Advisor at Advarra), and Jackie Kent (Independent Advisor) unpack the work of ACRO's dive team on representative, generalizable clinical trial data at the 2025 Innovation Network Gathering. Together, they explore why clinical trial populations still fail to reflect real-world patients, and what's been holding the industry back from meaningful progress.The conversation goes beyond identifying the problem. The group shares how a diverse set of stakeholders were able to align around practical, implementable solutions. They also discuss how industry can pilot new approaches, engage broader stakeholders, and turn promising ideas into standard practice. This episode offers a candid and solutions-oriented look at how to generate clinical data that truly supports better decision-making for all patients.

In this episode of the Gladden Longevity Podcast, Dr. Gladden and Leslie Kenny delve into the intricacies of aging, health, and the role of spermidine in promoting longevity. They discuss the hallmarks of aging, Leslie's personal journey with autoimmune conditions, and the importance of empowerment and curiosity in health management. The conversation emphasizes the interconnectedness of health factors and the need for a holistic approach to wellness. In this conversation, Leslie Kenny and Dr. Gladden explore the potential of spermidine as a breakthrough in aging research, discussing its effects on health, longevity, and cellular processes like autophagy. They share personal experiences with spermidine, the challenges of clinical research, and the importance of redefining aging. The conversation also highlights resources for healthy aging and the significance of mindset in health management.   For Audience Join the other 20,000+ high-performers getting weekly insights on biological reversal, exponential strategies, and Life Energy optimization→ https://start.gladdenlongevity.com/subscribe If you're ready to measure your 60+ biological ages and build a personalized reversal plan, apply for a discovery call here → https://start.gladdenlongevity.com/apply-now   Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/!    Takeaways ·       Spermidine positively impacts multiple hallmarks of aging. ·       Crosstalk between hallmarks of aging can enhance health. ·       Mindset plays a crucial role in health outcomes. ·       Patients should collaborate with their healthcare providers. ·       Curiosity in medicine leads to better patient outcomes. ·       The healthcare system often lacks time for curiosity. ·       Empowerment in health management is essential. ·       Modulating the immune system can restore balance. ·       Personal experiences can lead to significant health insights. ·       Holistic approaches to health can yield better results. Spermidine activates autophagy, aiding in cellular renewal. ·       Chronic management of illnesses is not desirable; patients want solutions. ·       Biological age can be significantly lower than chronological age. ·       Spermidine has potential benefits for heart health and cognition. ·       Personal experiences with spermidine show promising results in sleep quality. ·       Clinical trials for food-derived compounds face financial challenges. ·       The body can adapt and respond positively to the right inputs. ·       Redefining aging is crucial for a healthier future. ·       Mindset plays a vital role in health and aging. ·       Resources like Oxford Health Span can provide valuable information.       Chapters 00:00 Introduction to Longevity and Health 05:23 The Role of Spermidine in Aging 08:52 Personal Journey with Autoimmune Conditions 12:34 Empowerment in Health Management 18:07 The Importance of Curiosity in Medicine 25:21 Finding Balance in Immune Health 31:32 The Quest for Longevity and Health 34:58 Spermidine: A Breakthrough in Aging Research 39:14 Personal Experience with Spermidine 44:40 Challenges in Clinical Research 49:52 Redefining Aging and Health 52:52 Resources for Healthy Aging   To learn more about Leslie Kenny: Instagram: https://www.instagram.com/lesliesnewprime/ Website: oxfordhealthspan.com, lesliesnewprime.com   Reach out to us at:    Website: https://gladdenlongevity.com/     Facebook: https://www.facebook.com/Gladdenlongevity/    Instagram: https://www.instagram.com/gladdenlongevity/?hl=en     LinkedIn: https://www.linkedin.com/company/gladdenlongevity    YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw       Gladden Longevity Podcast Disclosures Production & Independence The Gladden Longevity Podcast and Age Hackers are produced by Gladden Longevity Podcast, which operates independently from Dr. Jeffrey Gladden's clinical practice and research at Gladden Longevity in Irving, Texas. Dr. Gladden may serve as a founder, advisor, or investor in select health, wellness, or longevity-related ventures. These may occasionally be referenced in podcast discussions when relevant to educational topics. Any such mentions are for informational purposes only and do not constitute endorsements. Medical Disclaimer The Gladden Longevity Podcast is intended for educational and informational purposes only. It does not constitute the practice of medicine, nursing, or other professional healthcare services — including the giving of medical advice — and no doctor–patient relationship is formed through this podcast or its associated content. The information shared on this podcast, including opinions, research discussions, and referenced materials, is not intended to replace or serve as a substitute for professional medical advice, diagnosis, or treatment. Listeners should not disregard or delay seeking medical advice for any condition they may have. Always seek the guidance of a qualified healthcare professional regarding any questions or concerns about your health, medical conditions, or treatment options. Use of information from this podcast and any linked materials is at the listener's own risk. Podcast Guest Disclosures Guests on the Gladden Longevity Podcast may hold financial interests, advisory roles, or ownership stakes in companies, products, or services discussed during their appearance. The views expressed by guests are their own and do not necessarily reflect the opinions or positions of Gladden Longevity, Dr. Jeffrey Gladden, or the production team. Sponsorships & Affiliate Disclosures To support the creation of high-quality educational content, the Gladden Longevity Podcast may include paid sponsorships or affiliate partnerships. Any such partnerships will be clearly identified during episodes or noted in the accompanying show notes. We may receive compensation through affiliate links or sponsorship agreements when products or services are mentioned on the show. However, these partnerships do not influence the opinions, recommendations, or clinical integrity of the information presented. Additional Note on Content Integrity All content is carefully curated to align with our mission of promoting science-based, ethical, and responsible approaches to health, wellness, and longevity. We strive to maintain the highest standards of transparency and educational value in all our communications.

Dr. Matthew Ithurburn, Director of Clinical Research at the American Sports Medicine Institute (ASMI) in Birmingham, Alabama, joins us to talk about the research shaping the future of sports medicine. Dr. Ithurburn leads ASMI's clinical research team, working alongside Andrews Sports Medicine and Orthopaedic Center on outcomes studies, longitudinal research, and surgical and biologic clinical trials. We dig into what this research means for athletic trainers on the ground, how it's translating into better outcomes for athletes, and where the next breakthroughs in injury prevention and recovery might come from.For more information about PBATS and athletic training, visit pbats.com. 

Rachel Sanborn, MD, Medical Director of Clinical Research, Robert W. Franz Cancer Center and Earle A. Chiles Research Institute - A Division of Providence Cancer Institute, Portland Oregon CME Credit Available for all Providence ProvidersIn order to claim CME credit, please click on the following link:⁠ ⁠ https://forms.office.com/r/YsSFEpMb5g⁠⁠⁠⁠ or copy & paste into your browser).Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1  creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Planning Committee & Faculty Disclosure: The planning committee have indicated no relevant financial relationships with an ACCME-defined ineligible company.Faculty:Since Dr. Sanborn is very involved in the research end of Medicine, she has a consulting role with various Pharmaceutic Companies and has presented research at their conferences and scientific meetings.  Any conflicts of interest will be addressed and mitigated for compliance to the commercialsupport and content validity guidelines of Providence Oregon Region CME prior to this live event. All financial relationships (if any) have been mitigated.Original Date: June 18, 2026End Date: June 17, 2027

Rachel Sanborn, MD, Medical Director of Clinical Research, Robert W. Franz Cancer Center and Earle A. Chiles Research Institute - A Division of Providence Cancer Institute, Portland Oregon CME Credit Available for all Providence ProvidersIn order to claim CME credit, please click on the following link:⁠ ⁠ https://forms.office.com/r/YsSFEpMb5g⁠⁠⁠⁠ or copy & paste into your browser).Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1  creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Planning Committee & Faculty Disclosure: The planning committee have indicated no relevant financial relationships with an ACCME-defined ineligible company.Faculty:Since Dr. Sanborn is very involved in the research end of Medicine, she has a consulting role with various Pharmaceutic Companies and has presented research at their conferences and scientific meetings.  Any conflicts of interest will be addressed and mitigated for compliance to the commercialsupport and content validity guidelines of Providence Oregon Region CME prior to this live event. All financial relationships (if any) have been mitigated.Original Date: June 18, 2026End Date: June 17, 2027

David Stamler, M.D., Chief Executive Officer AlterityTherapeuticsAlterity Therapeutics (NASDAQ: ATHE & ASX: ATH)www.alteritytx.com  David Stamler, M.D., Chief Executive OfficerDavid Stamler, M.D. is Chief Executive Officer and a Managing Director, and previously served as Alterity's Chief Medical Officer and Senior Vice President, Clinical Development. Dr Stamler has extensive drug development expertise spanning early-stage research through late-stage clinical trials, with three FDA drug approvals in neurology.Prior to joining Alterity, Dr. Stamler served as the Vice President, Clinical Development and Therapeutic Head for Movement Disorders at Teva Pharmaceutical Industries after Teva acquired Auspex Pharmaceuticals where he was Chief Medical Officer.Prior to Auspex, he served as Senior Vice President and Chief Medical Officer at XenoPort, Inc., and Head of Drug Development at Prestwick Pharmaceuticals, Inc. Before Prestwick, Dr. Stamler worked at Fujisawa Pharmaceutical Co. and its subsidiaries in various leadership roles, including Vice President, Research and Development, Medical Sciences at Fujisawa Healthcare, Inc., and as Vice President, Clinical Research Center at Fujisawa Research Institute of America. Dr. Stamler began his career at Abbott Laboratories where he served in various positions including Director of Clinical Research, Pharmaceutical Products for the International Division.Dr. Stamler received an M.D. from the University of Chicago—The Pritzker School of Medicine and a B.A. in Biology from the University of Chicago.

In today's episode, Haylie Pomroy sits down with neurologist Dr. Daniel Kantor, President Emeritus of the Florida Society of Neurology and VP of Clinical Research and Development at the Gateway Institute for Brain Research, for a conversation that challenges how most people think about unexplained symptoms, chronic illness, and the doctor-patient relationship. Dr. Kantor walks through why over-reliance on MRI results has left a generation of patients told nothing is wrong with them, why the nervous system, immune system, and gut microbiome communicate in ways most clinical silos never account for, and why gluten in the American food supply is a fundamentally different substance from what people eat in Europe. He also goes deep on the most disabling aspect of chronic illness, and it is not weakness or physical limitation. It is uncertainty.  One in five Americans lives with a chronic illness, and most of them go years before getting a diagnosis that helps them make sense of their experience. This conversation is for them. Tune in to Fast Metabolism Matters. If your body feels like it's running on empty, overburdened, or just not responding the way it used to, Haylie's latest book, Toxic Overload, tells you exactly what to do. Download your free digital copy today and start understanding what your body is trying to tell you.   Free Download: Get Your Copy of Toxic Overload

Artificial intelligence is reshaping clinical research, but its impact extends far beyond automation. In this episode of ACRO's Good Clinical Podcast, host Sophia McLeod is joined by Paulo Limgenco (VP, Business Operations at YPrime) and Michael Tucker (VP, Patient Experience - Commercial at Medidata) to explore how AI and digital technologies are helping the industry build more sustainable, efficient, and patient-centered clinical trials.From protocol optimization and site selection to localization and decentralized trial models, the conversation examines how AI can reduce operational burdens, minimize waste, and expand access to research opportunities for underrepresented populations. The discussion also highlights the importance of responsible AI adoption, including strong governance frameworks, data stewardship, and human oversight.Tune in for an insightful conversation on how the industry is balancing innovation and responsibility while working toward a future where clinical trials are more efficient, inclusive, and sustainable for patients, sites, sponsors, and communities worldwide.

Jaime's LinkedIn: https://www.linkedin.com/in/jaime-valles-2a1728221/My Free tools for sites and researchers: https://coordinare.co/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRC Academy: http://www.TheCRCacademy.comMy TikTok: DanSfera

In this episode, Dr Elle Wadsworth talks to Dr Amy Peacock, an Associate Professor and Deputy Director of the National Drug and Alcohol Research Centre, University of New South Wales, and Dr Krista Siefried, a Clinical Research Lead and Deputy Director, of the National Centre for Clinical Research on Emerging Drugs at the University of New South Wales, Australia. The interview covers two research articles: 1) Amy's article on trends in gamma-hydroxybutyrate (GHB) use, harms and treatment in Australia and 2) Krista's article on emergency department presentations, hospitalisations and police seizure data related to GHB in New South Wales, Australia.What is GHB? [01:30]Why is GHB an important drug to examine in the Australian population [02:30]The data sources Amy used in her study [04:20] The data sources Krista used in her study [06:45]The key findings of the study [08:21]Metabolites of GHB and risks of consuming GHB with alcohol [13:20]The implications of the findings for policy and treatment in Australia [14:04]The reasons behind the recent increase of GHB in Australia [16:30]The take home messages [19:14]About Elle Wadsworth: Elle is an academic fellow with the Society for the Study of Addiction. She is based at the University of Bath with the Addiction and Mental Health Group, and her research interests include drug policy, cannabis legalisation, and public health. Elle holds voluntary roles at The Loop, a non-profit service provider of drug checking in the UK and the International Society for the Study of Drug Policy. About Amy Peacock: Amy is an Associate Professor, National Health and Medical Research Council (NHMRC) Emerging Leadership Fellow and Deputy Director of the National Drug and Alcohol Research Centre, University of New South Wales. She is also Program Lead for Drug Trends, a national monitoring system identifying trends in illicit drug use, markets and harms that is funded by the Australian Government Department of Health, Disability and Ageing.About Krista Siefried: Krista is Clinical Research Lead and Deputy Director, the National Centre for Clinical Research on Emerging Drugs (NCCRED) at the University of New South Wales (UNSW) in Sydney, Australia. She is also a Senior Lecturer at the UNSW National Drug and Alcohol Research Centre (NDARC), and St Vincent's Hospital Sydney Alcohol and Drug Service. Krista works towards evidence-based interventions to reduce harm and improve healthcare for people who use drugs. Her leadership emphasises collaborative research, deep community engagement, and practical outcomes to address the needs of individuals, families, and frontline service providers.Declarations of interest: Krista is employed by the UNSW and St Vincent's Health Network Sydney, she has no other conflicts to declare. Original articles: Emergency department presentations, hospitalisations and police seizure data related to gamma-hydroxybutyrate (GHB) in New South Wales, Australia, from 2015 to 2024 https://doi.org/10.1111/add.70202 Trends in gamma-hydroxybutyrate use, harms and treatment in Australia, 2013 to 2024 https://doi.org/10.1111/add.70308The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal.The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information. Hosted on Acast. See acast.com/privacy for more information.

Kaye's LinkedIn: https://www.linkedin.com/in/kaye-doiron-209b5487/My Free tools for sites and researchers: https://coordinare.co/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRC Academy: http://www.TheCRCacademy.comMy TikTok: DanSfera

My Free tools for sites and researchers: https://coordinare.co/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRC Academy: http://www.TheCRCacademy.comMy TikTok: DanSfera

Elevated GP - Click here to join Elevated.GP Follow @dr.melissa_seibert on Instagram Dr. Peter Milgrom is Professor of Oral Health Sciences and Pediatric Dentistry in the School of Dentistry and adjunct Professor of Health Services in the School of Public Health at the University of Washington. He directs the Northwest Center to Reduce Oral Health Disparities. He holds academic appointments at Case Western University, University of Rochester, and University of California, San Francisco. He maintains a dental practice limited to the care of fearful patients and served as Director of the UW Dental Fears Research Clinic. Dr. Milgrom's work includes research on xylitol, the effectiveness of fluoride varnish and iodine in preschoolers, clinical efficacy and safety of diammine silver fluoride, motivational strategies to increase perinatal and well child dental visits in rural communities, and studies of cognitive interventions in pediatric and adult dental fear. The NIH, Maternal and Child Health Bureau, HRSA, and the Robert Wood Johnson Foundation support his work. Dr. Milgrom is author of 5 books and over 300 scientific articles. His latest book, Treating Fearful Dental Patients, was published in 2009.   Dr. Milgrom was Distinguished Dental Behavioral Scientist of the International Association for Dental Research for 1999. In 1999, and again in 2000, his work was recognized by the Giddon Award for research in the behavioral sciences in Dentistry. He received the Barrows Milk Award from IADR in 2000, recognizing his work for public health including the development of the Access to Baby and Child Dentistry (ABCD) program in Washington State. In 2003, Dr. Milgrom received a Special Commendation Award from the National Legal Aid and Defenders Association and the University of Washington Medical Center Martin Luther King, Jr. Community Service Award. In 2010, he received the Aubrey Sheiham Research Award for his work on xylitol. He serves on scientific review committees for the NIDCR, NIMHHD, NINDS, Center for Scientific Review at NIH and as a consultant to the FDA. In 2005, Dr. Milgrom was appointed the SAAD Visiting Professor of Pain and Anxiety Control at the King's College Dental Institute, University of London, UK for a six-year term. In 2008 he was awarded the degree of Doctor Honoris Causa from the University of Bergen, Norway in recognition of his work in social and behavioral dentistry. In 2012, he received the University of California, San Francisco Dental Alumni Gold Medal for his contributions to Dentistry. In 2012 he was also awarded the Norton Ross Award for Excellence in Clinical Research by the American Dental Association. In 2013, he was appointed to the Council of Scientific Affairs of the American Dental Association. In 2014, he received the Irwin M. Mandel Distinguished Mentor Award from the IADR. In 2015, he served as HMDP Expert in Dental Public Health for the Singapore Ministry of Health. Dr. Milgrom received his DDS from the University of California, San Francisco in 1972 and had a previous position at the National Academy of Sciences, Engineering, and Medicine. In the last few years, Dr. Milgrom has spoken to dental associations in Argentina, Colombia, Peru, Philippines, and USA and at major universities in USA and abroad.

What does it take to run successful clinical trials across borders? Tune in as Chris Boone (Group VP, Research, Health & Life Sciences at Oracle) and Alicia Baker McDowell (VP & Head of Global Regulatory Strategy at Fortrea) explore the shift from transactional outsourcing to truly co-created partnerships.They discuss how sponsors, CROs, and tech partners are redefining collaboration, tackling data fragmentation, and striking the right balance between global consistency and local execution to deliver more effective clinical trials worldwide.

The Gut 360 Podcast Episode 43: Dr Natalie Crawford: Fertility, PCOS, Egg Freezing, Inflammation + What To Know Before TTCThis episode dives into the connection between inflammation, insulin resistance and fertility, why PCOS is often misunderstood, what “trimester zero” really means, and the lifestyle habits that can genuinely support hormone health and conception. We also explore egg freezing, male fertility, environmental toxins, stress, sleep, exercise, and how fertility is often a reflection of overall health.Whether you are thinking about your future fertility, currently trying to conceive, navigating PCOS, or simply want to better understand your body, this episode is packed with empowering, practical insight.In this episode, we cover:Dr Natalie Crawford's personal fertility journey and how it shaped the way she cares for patientsWhy insulin resistance can silently impact ovulation, egg quality and implantationThe link between inflammation and PCOSCommon myths and misunderstandings around fertility and PCOSWhat “trimester zero” means and why preconception health mattersThe most impactful lifestyle habits to support fertility naturallyWhat an anti-inflammatory approach to eating looks like without becoming restrictiveHow sleep and circadian rhythm influence hormones and reproductive healthExercise and fertility: finding the balanceStress, inflammation and fertility without guilt or blameEgg freezing and what women should understand earlier about fertility and ageMale fertility and the overlooked role of sperm healthEnvironmental toxins and the simple swaps actually worth makingFind Eli Brecher here:LinkedIn | Eli BrecherEli Brecher Nutrition Website | www.elibrecher.co.ukEli Brecher Instagram | @elibrechernutritionSubscribe to Eli's Newsletter:www.subscribepage.io/join-my-inner-circleFind Dr Natalie Crawford here:Book: The Fertility Formula | nataliecrawfordmd.com/bookInstagram | @nataliecrawfordmdYouTube: Natalie Crawford, MDPodcast: As a WomanNatalie Crawford, MD is board certified in both Obstetrics and Gynecology and Reproductive Endocrinology and Infertility and is co-founder of Fora Fertility, a boutique fertility practice in Austin, Texas. Dr. Crawford is CEO and co-founder of Pinnacle, a professional network for women in medicine. She completed her undergraduate at Auburn University obtaining a degree in Nutrition Science, Medical School at UTMB, OBGYN Residency at UTSW, and REI Fellowship at UNC, concurrently obtaining a Master of Science in Clinical Research. Dr. Crawford is a digital health educator on social media, YouTube, and hosts the podcast  “As a Woman” with over 6 million downloads. Her debut book, “The Fertility Formula” was released by Penguin Random House._____________________________________________________________________________________About The Gut 360 PodcastWelcome to The Gut 360 Podcast with Eli Brecher, a Registered Associate Nutritionist with a passion for gut health. This podcast will provide nutrition tips, mindset tools and actionable steps to help you thrive on your journey to a healthier gut and a happier you. The mission of this podcast is to empower you to optimise your nutrition and transform your gut health using a 360° approach to wellbeing, so that you can reclaim your life and unlock your full potential.Sponsors:Get 8% off IM8 + a free welcome kit with your first order:https://im8health.com/discount/ELI Get 50% OFF ⁠The Cultured Collective's⁠ Kimchi & Sauerkraut at Sainsbury's via cashback app GreenJinn:·      ⁠I WANT KIMCHI⁠·      ⁠I WANT SAUERKRAUT⁠Click the link to add the coupon to your basket, sign in/create an account and after your purchase simply snap a photo of the receipt to get cashback straight to your Paypal or bank account. T&Cs apply.Follow for more insights, inspiration and recipes: ⁠@the_cultured_collective⁠

We discuss long term results of faricimab treatment of DME, with the first author of the Ophthalmology article on the results of Rhone-X trial, Dr. Veeral Sheth, Director of Clinical Research at University Retina in Chicago.

Learn how ashwagandha, rhodiola, ginseng, and black seed oil normalize stress responses without side effects—plus what science says about ThymoQuin. #Adaptogens #CortisolControl #NaturalEnergy

Luke's LinkedIn: https://www.linkedin.com/in/luke-snedaker-3511b18a/My Free tools for sites and researchers: https://coordinare.co/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRC Academy: http://www.TheCRCacademy.comMy TikTok: DanSfera

Send us Fan MailPost-thrombotic syndrome (PTS) affects up to half of patients following deep vein thrombosis and can significantly impair quality of life. Yet treatment options have historically been limited.In this episode of CLOT Conversations, David Airdrie and Dr. Jameel Abdulrehman speak with Dr. Susan Kahn about the recently published C-TRACT trial in The New England Journal of Medicine.The trial evaluated whether endovascular therapy, including iliac vein stenting, could improve outcomes for patients with moderate-to-severe post-thrombotic syndrome and iliac vein obstruction.Dr. Kahn discusses the rationale behind the study, key findings related to symptom burden and quality of life, the increased bleeding risk observed with intervention, practical patient selection considerations, and the unanswered questions that remain regarding long-term management after venous stenting.This episode provides clinicians with practical insights into one of the most important recent studies in the management of post-thrombotic syndrome.Reference:Vedantham S, Kahn SR, Marston WA, Weinberg I, Sista AK, Magnuson EA, Cohen DJ, Wasan SM, Razavi MK, Goldhaber SZ, Sanfilippo KM. Endovascular Therapy for Post-Thrombotic Syndrome—A Randomized Trial. New England Journal of Medicine. 2026 Apr 13.https://www.nejm.org/doi/abs/10.1056/NEJMoa2519001Support the showhttps://thrombosiscanada.caRegister today for our upcoming conference on November 7, 2026 in Montreal at https://thrombosiscanada.ca/2026ConferenceTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

At the 2025 AAHKS Annual Meeting, our hosts William B. Kurtz, MD and Matthew W. Bullock, DO sat with Matthew S. Hepinstall, MD, FAAOS and Kyle L. McCormick, MD, the 2025 Clinical Research Award winners to discuss their study “Maximizing Bearing Diameter Markedly Lowers Dislocations in Primary Total Hip Arthroplasty” that was presented at the AAHKS Annual Meeting.   Prevention of dislocation is a topic of interest for Drs. Hepinstall and McCormick which is what prompted this study that consisted of over 8,000 patients who underwent fixed-bearing THA. Because modern polyethylene allows larger bearings in fixed-bearing THA, stability benefits of fully maximizing bearing diameter (e.g. 36-mm in 48/50-mm cups) are not well established. Drs. Hepinstall and McCormick discussed on the podcast the number of dislocations in the study with patients with maximized bearing diameters and how certain variables such as age, sex and body-mass index help to protect against dislocation.  For more on how fully maximizing bearing diameter reduced dislocation odds in primary fixed-bearing THA, listen to the full podcast. Don’t forget to subscribe and thanks for listening to AAHKS Amplified! In This Episode:Matthew W. Bullock, DO Matthew S. Hepinstall, MD, FAAOSWilliam B. Kurtz, MDKyle L. McCormick, MD  The post The 2025 AAHKS Clinical Research Award Winner first appeared on AAHKS.

My Free tools for sites and researchers: https://coordinare.co/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRC Academy: http://www.TheCRCacademy.comMy TikTok: DanSfera

Artificial intelligence is rapidly reshaping the landscape of rare disease research -- but how close are we to realizing its full potential? In this episode, Tanya Binette (Director of Therapeutic Expertise, Rare Disease at ICON plc) and Roz Round (SVP of Operational Strategy, Patient and Site Engagement at Precision for Medicine) explore how AI is being applied across the rare disease clinical trial lifecycle, from drug discovery and protocol design to patient identification and engagement.The discussion highlights both the promise and complexity of using AI in a research space defined by small patient populations, fragmented data, and unique ethical considerations. Guests emphasize the importance of patient trust, regulatory alignment, and responsible innovation, while also identifying opportunities to accelerate trials, improve access, and empower patients through AI-enabled tools.

My Free tools for sites and researchers: https://coordinare.co/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRC Academy: http://www.TheCRCacademy.comMy TikTok: DanSfera

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences.In this episode, Dr Camidge sat down with Karen L. Reckamp, MD, director of Medical Oncology, associate director of Clinical Research, and the medical oncology director of the Lung Institute at Cedars Sinai in Los Angeles, California.Drs Camidge and Reckamp discussed Dr Reckamp's journey as an oncology specialist and now a caregiver for her husband, who has cancer. Reckamp's career was inspired by her family's history with BRCA-related cancers. She pursued an academic path that eventually led her to Los Angeles, where she became a leader in thoracic oncology during an era of genomic breakthroughs.In late 2024, her husband, a fellow oncologist, was diagnosed with pancreatic cancer shortly after a clear annual scan. Reckamp described the jarring transition of receiving the diagnosis and the ensuing emotions balanced with medical pragmatism. Bob underwent intensive treatments that have affected his physical health and daily life.Reckamp offered a candid look at the dual role of a physician-caregiver. She continues to work, however, her husband's cancer diagnosis has changed her practice. Now, she is more sensitive to chemotherapy toxicities in her patients that she might have previously minimized. She also highlighted the invisible load of caregivers who must manage their own emotions and remain available for patient needs.Ultimately, Reckamp emphasized the necessity of a support network, crediting their long-time nanny and overall community with maintaining her family's stability. By allowing different people to hold different pieces of the emotional burden, Reckamp shared that her family is finding a way to move forward amidst the uncertainty of this cancer diagnosis.

Generative AI and other technologies are transforming clinical research and trials. Find out how it's done.     The clinical trials sector is risk-averse, heavily regulated, and not often thought of as a technology first-mover. How is Merck changing that perception by using AI to improve insights, innovation, and operations?     Join Steve Odland and guest Jennifer Sheller, senior vice president and head of global clinical trial operations at Merck, to find out how the company is using AI for clinical research and clinical trials, why "human in the loop" remains essential, and how Merck thinks about the ethical, safety, and privacy considerations of digital health.     For more from The Conference Board:  How AI Can Help Remedy the US Health Care Workforce Crisis  Health Care Workforce Policy Summit: Insight Summary  Navigating the Health Care Landscape in 2026 

Site feasibility remains a critical yet complex component of clinical trial startup. In this episode, listen as Andrea Bastek (VP, Market Strategy at Florence Healthcare), Christine Senn (SVP, Site-Sponsor Innovation at Advarra), and Ashley Davidson (SVP, Head of Product at Advarra) unpack the persistent challenges in feasibility -- from manual, time-intensive processes and data trust gaps to misaligned timelines and limited transparency between stakeholders.The conversation explores how collaboration, smarter process design, and emerging technologies like AI and real-time data integration can reduce burden on sites and improve study startup timelines. Guests also share practical recommendations, including simplifying CDA processes, improving communication between sponsors and sites, and leveraging data more effectively to move forward toward a more efficient and connected feasibility model.Resources:- Advarra CDA Template - Advarra Site ID Feasibility Solution- Paper from Florence Healthcare's Site Enablement League

Send us Fan MailWhen T.J. Sharpe was diagnosed with stage 4 melanoma at just 37 years old, the statistics were devastating. With a newborn son, a two-year-old daughter, and limited treatment options available at the time, he faced a life-changing decision: pursue standard chemotherapy or take a chance on early immunotherapy clinical trials.In this powerful episode of the MedEvidence Podcast, cardiologist and medical researcher Michael Koren sits down with T.J. to discuss his remarkable journey from cancer recurrence and uncertainty to becoming a long-term survivor through groundbreaking clinical research.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

My Free tools for sites and researchers: https://coordinare.co/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRC Academy: http://www.TheCRCacademy.comMy TikTok: DanSfera

What does "patient-centricity" actually look like in practice, and why does it still fall short? In this episode, Stacy Hurt (Chief Patient Officer at Parexel) and Alicia Staley (Chief Patient Officer at Medidata) bring both lived experience and industry insight to a powerful discussion on the gaps between intention and reality in clinical research. They unpack the emotional and logistical challenges patients face, from navigating fragmented systems to feeling dismissed by well-meaning but unhelpful messaging. The discussion highlights the need for systemic thinking, stronger partnerships with advocacy communities, and greater adoption of patient leadership roles. With real-world examples and a forward-looking perspective, this episode offers a roadmap for turning patient-centricity into tangible change.

Send us Fan MailPregnenolone, a neurosteroid derived from cholesterol, affects brain activity and shows promise for treating mood and substance abuse disorders.TOPICS DISCUSSED:Steroid Biosynthesis: Cholesterol converted to pregnenolone, the precursor for all steroid hormones including cortisol, aldosterone, and sex hormones.Corticosteroids: Synthetic versions like prednisone primarily target glucocorticoid receptors for anti-inflammatory uses but can impact mood and cognition.Pregnenolone Mechanisms: Positive allosteric modulator of NMDA receptors for cognition and negative allosteric modulator of CB1 cannabinoid receptors.Allopregnanolone: GABAergic derivative of pregnenolone; its IV form Brexanolone is FDA-approved for postpartum depression.Clinical Trials: Pregnenolone at 100-500 mg improved depressive symptoms in placebo-controlled studies of bipolar disorder patients.Cannabis Interaction: THC robustly induces brain pregnenolone production; supplementation may reduce cannabis and alcohol use.Corticosteroid Brain Impact: Prednisone use associated with smaller hippocampal volumes and memory deficits.ABOUT THE GUEST: Sherwood Brown, MD, PhD is Vice Chair for Clinical Research in the Department of Psychiatry at the University of Texas Southwestern Medical Center in Dallas. With a background in chemistry, his research focuses on steroids and comorbidities in people with mood disorders.RELATED EPISODE:M&M 124: Hormonal Contraception, Sex Hormones, Menstruation, Pregnancy, Puberty, Estrogens, Androgens, Effects of Birth Control on Cognition | Adriene BeltzSupport the showHealth Products by M&M Partners:AquaTru: Water filtration devices that remove microplastics, metals, bacteria, and more from your drinking water. Through link, $100 off AquaTru Carafe, Classic & Under Sink Units; $300 off Freestanding models.OmegaQuant: At-home blood testing to see fatty acid profiles, including omega-3 fatty acids. Use link to see options and support M&M.SiPhox Health: Comprehensive, cost-effective bloodwork from the comfort of home. Use code TRIKOMES for 20% off.KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime)Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app.SporesMD: Premium mushrooms products (gourmet mushrooms, nootropics, research). Use code 'nickjikomes' for 20% off.For all the ways you can support my efforts

My Free tools for sites and researchers: https://coordinare.co/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRC Academy: http://www.TheCRCacademy.comMy TikTok: DanSfera

Co-hosts Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Science Advisory Council, interview Dr. Chukwuemeka Oko, MD, MBA, on clinical trials. Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [:49] Co-host Ryan Piansky introduces this episode, brought to you thanks to the support of Education Partners GSK, Sanofi, Regeneron, and Takeda. Ryan introduces co-host Holly Knotowicz.   [1:13] Holly introduces today's topic — clinical trials — and today's guest, Dr. Chukwuemeka Oko, a Clinical Research and Medical Affairs Professional supporting Duke University Hospital's Department of Gastroenterology and Transplant Hepatology.   [1:33] Dr. Oko explains that he is sharing general, educational information from his perspective and experience, not speaking on behalf of Duke University, nor any industry sponsor, nor any company he has worked for.   [1:50] Dr. Oko's goal today is to help the listeners feel clearer, more confident, and more in control when they are thinking about clinical research.   [2:29] Dr. Oko's work sits mainly at the intersection of clinical research and medical affairs. He helps translate evolving science into practical, patient-centered decisions.   [2:40] From an academic standpoint, he supports clinical trials and evidence generation from feasibility through education.   [2:49] Dr. Oko also engages investigators and thought leaders from industry sponsors in scientific exchanges that lead to insights, study design, and real-world care pathways.   [3:03] Dr. Oko had two reasons to study eosinophilic esophagitis and eosinophilic disease. The first is the patient journey and biology.   [3:11] On the patient side, many people spend a long time seeking answers. Sometimes they feel dismissed before they get a clear diagnosis and a plan that fits their life.   [3:24] On the biology side, eosinophilic disease teaches us a lot about how our immune signals can drive information differently across tissues like the esophagus and airways.   [3:40] Dr. Oko supported an EoE study experience with an industry sponsor in the past. The best research doesn't just test; it helps patients and clinicians make clearer decisions.   [4:12] Dr. Oko explains that a clinical trial is a carefully designed, carefully crafted study in people that answers specific medical questions, most often about safety, effectiveness, or dosing of the study drug or how a treatment should be used.   [4:32] A key structure of a study is a written protocol where safety monitoring is in place, and the defined outcome or results are very reliable. The FDA always oversees clinical trials in the U.S.    [4:44] Dr. Oko often describes a trial as a highly-monitored learning system. It's how medicine moves from "We think this might help" to "We know what helps, for whom, and also at what risk."   [5:09] Dr. Oko says clinical trials usually study what improves patient outcomes, for whom, and at what risk, using methods that we can trust. Trials may evaluate new medicines, devices, dosage strategies, or even procedures.   [5:31] Clinical trials can also study non-drug approaches such as diet interventions, symptom tracking, monitoring tools, and education strategies.   [5:44] Many trials have also included biomarkers, or signals in the blood or tissue, helping to support an EoE diagnosis so that the patients can get treated in an early and effective manner.   [6:36] Dr. Oko says patients sometimes ask him if they are guinea pigs. In reality, trials are heavily regulated and closely monitored, with strict safety reporting requirements. Participants are not guinea pigs.   [7:06] Dr. Oko also hears patients ask if they are "stuck" once they join the clinical trial. No, a trial is a completely voluntary participation, and they can withdraw at any time.   [7:25] Other patients ask if trials are only for people who are out of options. Many trials are designed for earlier stages, especially when the goal is to prevent complications or reduce steroid exposure.   [7:46] The last question Dr. Oko hears a lot is "Will I be in the placebo group?" He says it's an understandable fear. They are asking if they will go untreated in the placebo group.   [8:29] In many trials, a placebo is not the same as "no care". Often, the participants continue the standard-of-care treatment, and the study drug or placebo is added to the standard-of-care treatment.   [8:45] Trials typically involve symptom monitoring and a plan for what happens if the symptoms worsen. There are exit criteria.   [9:01] From the pharmaceutical side, it's the end of treatment once you decide to voluntarily exit the study.   [9:10] Dr. Oko's advice is, if you participate, ask the study team physicians to explain in plain language what you'll receive, what you can continue, and what happens if you flare up. Clear answers are always a part of ethical research.   [10:33] Holly asks what it means to participate in a Phase 1, Phase 2, or Phase 3 trial. Dr. Oko says a Phase 1 trial is focused mostly on the safety and the dosing regimen. It's usually a small group of five to 100 or so.   [10:52] A Phase 2 trial always looks for the drug's effectiveness and continues monitoring safety. It's usually a group of 100 to 300 subjects. They look for meaningful signals of the outcomes derived from the trial.   [11:10] A Phase 3 trial is usually large. It's multi-centered. It's called a complementary study. It involves thousands of patients. It can even be across nations and states.   [11:26] This is where they compare new interventions against a placebo or against a standard of treatment to provide clinical benefits and support for regulatory approval.    [12:03] Participating in any phase of a trial includes fitting the eligibility criteria of inclusion for that particular phase. If you are a good match, you can be in either a Phase 1, Phase 2, or Phase 3 trial.   [12:52] Holly says she knows that a lot of people with EoE or EGIDs are very curious about trials and how to participate in them.   [13:00] Ryan says we have a very active patient community, and everyone's looking for ways to get involved in research and new diagnostics or medications to improve their own outcomes and help everyone else.   [13:35] Dr. Oko says the benefits of participating in a clinical trial include access to potentially disease-modifying therapies years before they reach the market.   [13:47] Another benefit is extraordinarily close medical monitoring. When you're in a clinical trial, you have more frequent visits and more frequent labs than usual.   [14:01] Endoscopies are out of the normal standard of care, but will be more frequent than normal to analyze the efficacy of the study drug.   [14:11] Dr. Oko says one of the risks is the unknown side effects the study drug comes with, because we are still understanding the biology.   [14:21] The time commitment for visits can be more than typical for a patient, especially if there is a long travel time involved. Patients may arrive at 7:00 or 8:00 a.m. They may need to find a place to live nearby, depending on the pace of the trial.   [14:57] Holly lives in Maine, and a lot of the trials are in Boston. It's a lot of travel. For people with any kind of chronic illness, all we think about is money. Holly asks if people pay to be part of a clinical trial.   [15:25] Dr. Oko states that the patients do not have to pay anything to be part of a clinical trial. Patients do get compensated by the trial sponsor for travel, accommodation, parking, and a meal for the days they are onsite.   [16:33] Dr. Oko says that patients tend to bring up insurance. It is a misconception that the study will pay for their standard-of-care medication during the study. Patients need to ask the study team what insurance will pay for and what the study will pay for.   [16:59] Dr. Oko says the insurance usually covers the regular standard-of-treatment, but any other additional treatment, procedures, and visits are all covered by the study sponsor.    [17:29] The study sponsor may ask for an endoscopy to be done six months before the study to determine eligibility for the study. If it is done within a year, the study sponsor will determine if you are qualified. That is part of the eligibility criteria in some cases.   [18:26] Dr. Oko tells patients to always ask questions, like what the schedule of events is in the clinical trial.   [18:35] The schedule of events tells you how many visits are required for you to be part of this study. They will list the activities to be done. They will list the labs you will need at what week. They will list when you need endoscopies, at week one and later.   [19:05] If you exit from the study, if you don't want to participate anymore, you are still required to come on site just to make sure that you are in good shape. Those are called formal visits.   [10:29] Dr. Oko explains that formal visits are necessary for the patient's safety and to make sure that the data points collected in the study will be effective.   [20:01] Patients enrolling in a clinical trial can also ask about the known risks of the symptom monitoring plan. They can ask what is covered and what is not covered by insurance, and what will be considered out of pocket.   [20:20] If patients are in the placebo group, what will happen if symptoms worsen? In the protocol, there is always a rescue plan. If a symptom flares up, the Principal Investigator carries out the rescue plan.   [20:58] The study team is available on a 24/7 hotline. The questions you ask are very important. No question is too small to ask. Every question and every symptom you report is important. You can withdraw at any time, and there is always a follow-up.   [22:19] Dr. Oko says the trial data that has already been collected from part of our eosinophilic studies has led to various FDA approvals of the biologics. We are working  to try to transform EoE from a steroid-dependent or diet-only disease into a position of long-term control.   [22:37] Trial findings have shaped care, expanding evidence-based options, clarifying which patients benefit the most, and improving how we measure our outcomes, the symptoms, and quality of life, as measured by patients' quality-of-life surveys.   [23:06] Quality-of-life surveys are very important for the study team. They help to measure safety, too. The evidence generated from this data leads to insights and improves study design, protocol design, and ultimately, improves patient care.   [23:40] Ryan says the community is interested in clinical trials because they benefit patients, researchers, and clinicians. We're thankful for the clinicians and researchers putting in all the work to make these clinical trials happen.   [24:01] Ryan adds, we're also thankful for the patients who are interested in these trials. For patients who are looking to participate, how can they find clinical trials to participate in and join?   [24:15] Dr. Oko says people can find the website ClinicalTrials.gov. It's an important tool in looking for various clinical research. Scientists are recruiting at a given time. You can use the Advanced Search option to narrow the search by state and criteria.   [24:54] You can always discuss clinical trials with your primary care physicians. You can look for major academic medical centers. Most of them always have clinical research studies going on.   [25:07] Dr. Oko says APFED.org is a very good tool. It always maintains up-to-date trial listings and patient-friendly summaries where patients can read about the studies.   [25:30] Ryan says he's very appreciative of the mention of APFED. There is a link on APFED.org so people can find studies. There are clinical trials listed that people can research more and join.   [25:46] Holly asks Dr. Oko to share advice for listeners who are considering participating in a clinical trial. He shares, "I want each one of you to approach the decision with the same care you would with any major medical choice. Review the Informed Consent Form (ICF)."   [26:23] "The word informed means you should be informed. It's your right to get informed with every line, every detail. The Consent Form can be 30 pages long, but please just know that you are not in a rush to answer."   [26:43] "You can take the Consent Form and discuss it with your friends, your family, your primary care physician, your gastroenterologist, and your allergist and get more information."   [27:00] "When you join an interventional trial, or a registry, your contribution accelerates the science and benefits the entire eosinophilic community."   [27:12] "From my years of reviewing medical charts and supporting new recruitments, I feel patients feel most satisfied when they are fully informed and genuinely partnered with the study team. That's how I partner with the patients. I am always there to help."    [27:40] Ryan says that is great advice for patients, and hopefully, some of our listeners to this episode will go out there and look for clinical trials to participate in or ask their physicians, next time they're getting care.   [27:52] For patients who would like to know more about eosinophilic disorders, we encourage you to visit APFED.org and check out the links in the show notes below, specifically to research opportunities listed on APFED.org. [28:08] If you've been personally impacted by eosinophilic disorders and are interested in sharing your experiences, we encourage you to please check out APFED.org/shareyourstory.   [28:17] Ryan thanks Dr.Oko for joining us today. This was really helpful and insightful, and hopefully, we'll have many new patients interested in joining clinical trials. Dr. Oko thanks Ryan and Holly for having him on and thanks every listener who has joined us.   [28:33] Dr. Oko says it has been a genuine pleasure and privilege for him. He has spent years seeing patients, reviewing their charts, and hearing their stories. We see you, we hear you. Science is advancing rapidly and shaping outcomes. You are not alone.   [30:17] Holly thanks Dr. Oko for his research and clinical trials, and thanks APFED's Education Partners GSK, Sanofi, Regeneron, and Takeda for supporting this episode.   Mentioned in This Episode:   APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast Apfed.org apfed.org/specialist apfed.org/connections apfed.org/research/clinical-trials Duke University Hospital's Department of Gastroenterology Education Partners: This episode of APFED's podcast is brought to you thanks to the support of GSK, Sanofi, Regeneron, and Takeda.   Tweetables:   "Many people spend a long time seeking answers. Sometimes they feel dismissed before they get a clear diagnosis and a plan that fits their life." — Chukwuemeka Oko, MD, MBA   "On the biology side, eosinophilic disease teaches us a lot about how our immune signals can drive information differently across tissues like the esophagus and airways." — Chukwuemeka Oko, MD, MBA   "In many trials, a placebo is not the same as no care. Often, the participants continue the standard-of-care treatment, and the study drug or placebo is added to the standard-of-care treatment." — Chukwuemeka Oko, MD, MBA   "I tell patients to always ask questions, like what the schedule of events is in the clinical trial." — Chukwuemeka Oko, MD, MBA   "[If a patient exits the study], formal visits are necessary for the patient's safety and to make sure that the data points collected in the study will be effective." — Chukwuemeka Oko, MD, MBA   "From my years of reviewing medical charts and supporting new recruitments, I feel patients feel most satisfied when they are fully informed and genuinely partnered with the study team." — Chukwuemeka Oko, MD, MBA   Guest Bio: Chukwuemeka Oko, MD, MBA

In this episode of The Clinical Research Coach, host Leanne Woehlke sits down with Angela Radcliffe for a powerful conversation about empathy, innovation, and why the future of clinical research must remain deeply human.Angela shares the personal experiences that shaped her passion for healthcare and clinical research, including the profound impact clinical trials had on her own family. Together, Leanne and Angela explore how the industry can embrace AI and emerging technologies without losing the trust, compassion, and human connection patients need most.From patient experience and purpose-driven leadership to the balance between technology and empathy, this episode is a reminder that innovation works best when it serves people first.If you care about the future of clinical research, patient trust, and keeping humanity at the center of healthcare innovation, this conversation is one you won't want to miss.Learn More:About Angela:Angela Radcliffe is a dynamic speaker, best-selling author, and impact influencer who advocates for teaching children (ages 8-14) health, data and AI literacy to provide them with the necessary skills and knowledge to thrive in a data-driven world. She's the author of “Quantum Kids Guardians of AI”, an activity book that introduces elementary and middle school students to AI fundamentals through seven engaging missions. The book weaves concepts like neural networks, large language models, data ethics, and prompt engineering into relatable stories about school, social media, and robotics. It empowers young readers to: - Apply AI knowledge to homework and hobbies- Navigate Internet safety - Understand technology's role in addressing societal challenges- Make informed decisions about health and personal data protection.With 20+ years of experience, Angela drives progress in medical research, healthcare marketing, and healthcare data and artificial intelligence. She understands the intricate interplay of trust, value, and risk in unleashing power from petabytes of data. Frequently at the helm of global endeavors, including as Head of Digital Performance Improvement and Innovation for Research and Early Development IT, Head of Enterprise Digital Strategy Innovation, and Head of Enterprise Data Governance at Bristol Myers Squibb, she's orchestrated transitions from molecular concepts to market-ready solutions and from boardroom strategies to tangible implementations that transform customers into champions. Over the years, Angela has worked closely with thousands of patients participating in clinical trials, partnered seamlessly with tech luminaries and stood shoulder-to-shoulder with industry peers with a single focus: pushing, often pulling, clinical research and healthcare forward. Angela's compelling thought leadership combines technical insights on AI's growing impact with her personal stories of overcoming adversity. Her experiences such as growing up poor, leaving an abusive spouse, losing her 21-year-old brother to an undiagnosed heart condition, and raising a neurodivergent daughter fuel her mission to advance health, data and AI literacy. This unique background and her stellar communications and interpersonal skills make her a sought-after speaker for podcasts and with life sciences, patient education, mental health, data privacy, teacher and parent organizations.Connect with Angela Radcliffe on LinkedIn:https://www.linkedin.com/in/angela-radcliffe-2560256/Angela's Website:https://intelligenceapplied.ai/Angela's Books:The Five Laws of Applied Intelligence: Why Your Humanity Is Your Superpower and How to Use It to Win in a World of Machines Quantum Kids Guardians of AI: Story Quest and Activity Book

Southern Remedy Healthy and Fit is hosted by Josie Bidwell, Professor of Preventive Medicine and Nurse Practitioner at UMMC. If you have a question for Josie, you can email fit@mpbonline.org. It this episode, Josie talks about clinical research and studies with Dr. Matthew Kutcher, a trauma and acute care surgeon at UMMC and Chris Moore, Director of Clinical Research at UMMC. If you enjoy listening to this podcast, please consider contributing to MPB. https://donate.mpbfoundation.org/mspb/podcast. Hosted on Acast. See acast.com/privacy for more information.

What happens when clinical trial sites are given the resources and autonomy to determine precisely what their site needs to be successful? In this episode, participants from the ACRO Site Grants Program share how targeted funding helped them tackle real-world barriers to clinical trial access and diversity. From community-based outreach and patient education, to internal infrastructure and staffing, these sites implemented tailored solutions designed to meet the unique needs of their communities. Along the way, they encountered challenges, adapted their approaches, and uncovered valuable lessons about trust-building, flexibility, and long-term engagement.This conversation highlights how even small investments can drive meaningful change at the site level, and what the broader industry can learn from these experiences.

My Free tools for sites and researchers: https://coordinare.co/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRC Academy: http://www.TheCRCacademy.comMy TikTok: DanSfera

My Free tools for sites and researchers: https://coordinare.co/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRC Academy: http://www.TheCRCacademy.comMy TikTok: DanSfera

Artificial intelligence is reshaping every stage of drug development, but unlocking its full potential requires more than technology alone. In this episode, Clay Alspach (Executive Director, ACRO) Raja Shankar (VP of Machine Learning at IQVIA), and Andrew Mackinnon (SVP & Executive General Manager at Medable) come together to examine how policy, regulation, and global collaboration will shape the future of AI in clinical trials.From breaking down data silos to addressing regulatory uncertainty and enabling a “try first” mindset, the discussion highlights both the opportunities and the complexities ahead. With insights on patient impact, site experience, and the next wave of innovation, this episode offers a roadmap for advancing AI in a way that is both responsible and transformative. 

My Free tools for sites and researchers: https://coordinare.co/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Why do qualified candidates apply to role after role in clinical research and never hear back? In this episode of the Clinical Trial Podcast, we unpack what's really happening behind the scenes in the hiring process. Getting hired isn't just about your technical skills. It's about how hiring managers assess risk, how recruiters decide who to champion, and who actually gets attention versus who gets ignored. Kunal Sampat is joined by Giovanni Lauricella, Co-Founder and CEO of Lifeblood, an executive search firm specializing in MedTech. With over 15 years of experience placing board members, C-suite leaders, and cross-functional talent globally, Giovanni brings a unique perspective from inside the hiring process. In this episode, you'll learn: Why strong candidates get filtered out before interviews What hiring managers are actually looking for How recruiters decide who to advocate for What it really takes to break into and advance in clinical research If you've ever felt stuck in your job search or wondered why the process feels like a black box, this conversation will give you a clearer understanding of how hiring decisions are actually made.

In this episode of Disruption/Interruption, host KJ sits down with Ome Ogbru, PharmD, CEO and founder of AINGENS, to tackle a decades-old problem hiding in plain sight: life sciences runs on groundbreaking science, but is buried in broken processes. After 20+ years as a clinician, professor, and pharmaceutical executive, Ome reached a breaking point, and instead of finding a new job, he built a new company. He shares how generative AI, used responsibly and strategically, can finally give researchers their time back, cut through misinformation, and help the right information reach the right people faster. Four Key Takeaways: The scientific content workflow is fundamentally broken [4:15] -- Research teams are so resource-strapped that PhDs spend their time managing IT systems instead of doing science. Procuring a software solution could take one to two years and often didn't even solve the right problem. Generative AI isn't the magic wand, it's how you use it [20:01] -- When Ome first tested ChatGPT on biotech content and got poor results, he had a revelation: the tool wasn't the problem. The problem was not knowing how to use it. Pairing AI with deep domain expertise and proper workflows is where the real power lies. The human expert must remain in the driver's seat [32:30] -- AINGENS' platform (MACG) is built so the professional is in control. The AI handles the time-consuming, mundane tasks like literature search, drafting, and formatting, while the expert applies regulatory knowledge, judgment, and guardrails. Misinformation in life sciences is a public health problem [35:49] -- Misinformation travels faster than accurate data. Ome's vision is for generative AI to help industry proactively get accurate, personalized scientific information to the people who need it, patients, clinicians, and researchers alike, before the noise wins. Quote of the Show (35:41):"Misinformation flies faster than correct information." -- Ome Ogbru Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Ome Ogbru:LinkedIn: https://www.linkedin.com/in/ome-ogbru-pharmd/Company Website: http://www.aingens.com How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

My Free tools for sites and researchers: https://coordinare.co/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Theo Jaffee and Gabriel Dickinson speak with Cremieux about China's rapid rise to the top of global clinical trial output. They discuss the regulatory reforms that accelerated China's progress, the surge in novel drug development, and what the US would need to change to stay competitive in biomedical innovation.   Resources: Follow Cremieux on X: https://x.com/cremieuxrecueil Follow Theo on X: https://x.com/theojaffee Follow Gabriel on X: https://x.com/gbrl_dick   Stay Updated:Find a16z on YouTube: YouTubeFind a16z on XFind a16z on LinkedInListen to the a16z Show on SpotifyListen to the a16z Show on Apple PodcastsFollow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Tracy Morgan is a psychoanalyst in private practice in NYC seeing individuals, couples and groups. She is a member of the faculty at CMPS, a founding member of Das Unbehagen and the founding editor of the award winning podcast New Books in Psychoanalysis. She has published on a variety of subjects ranging from Gay and African American history, social movement theory, and psychoanalysis. Her most recent publication, Must We Drown in the Wake? Notes on Addressing Racism at Psychoanalytic Institutes was recently published in the journal Group. And the essay was nominated for a Gradiva Award for best article in the field in 2025. Ashis Roy, PhD, is a psychoanalyst and scholar affiliated with the Indian Psychoanalytical Society (Kolkata) and the International Psychoanalytical Association (London). His clinical practice serves adults, young adults, and couples, informed by over a decade of pedagogical and institutional leadership. Previously, as a faculty member at the Centre of Psychotherapy and Clinical Research, Ambedkar University, Dr. Roy was instrumental in institutional development and the clinical training of psychoanalytic psychotherapists. Currently, he serves on the faculty of the China-American Psychoanalytic Alliance (CAPA). His research resides at the intersection of clinical praxis and cultural psychoanalysis, with a specialized focus on the application of psychoanalytic frameworks to Asian and South Asian sociocultural contexts. An active contributor to international scholarly dialogue, he hosts psychoanalytic segments for the New Books Network. Dr. Roy is the author of the book Intimacy in Alienation: A Psychoanalytic Study of Hindu-Muslim Relationships (Yoda Press, 2024), which examines the psychodynamic complexities of inter-communal intimacy. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/psychoanalysis

Vincent Drouillon, Vice President of Global Central Lab Strategy and Growth at CTI, discusses how central laboratory services support clinical trials. He shares his path into laboratory medicine, explains why early collaboration and partnership are key to trial success, and outlines how global alignment and integrated lab solutions help sponsors move medicine forward. 00:36 Overview of Vincent's role and background in laboratory medicine and clinical research.01:18 Vincent's career path and what drew him to central laboratory services.02:37 The global impact of central labs and their role in developing new medicines.03:44 Why global collaboration and diverse perspectives matter in central lab work.04:28 Recognizing laboratory professionals and the importance of Lab Week.05:26 Leading growth, scalability, and strategy for CTI's central lab services.06:55 How CTI's quality-focused, flexible, and holistic approach differentiates its lab services.07:54 Supporting complex and integrated clinical trials across specialized therapeutic areas.09:29 Why lab planning and logistics are often underestimated in trial design.11:19 The value of early engagement to reduce risk and prevent downstream delays.14:39 Emerging capabilities shaping the future of laboratory services, including AI, analytics, and personalized medicine.17:12 Closing reflections on partnership, patient impact, and the role of laboratories in moving medicine forward.

Most people think better skin comes from doing more, but the biggest impact comes from doing a few things consistently.  Dr. Lawrence Bass and clinical dermatologist Dr. Jennifer Vickers share the essentials that actually move the needle, from daily sunscreen to simple, effective skincare. They cover what matters most for maintaining skin quality, where office treatments fit in, and why a straightforward routine often delivers the best long-term results. When you keep it simple and stay consistent, your skin has a much better chance of aging well. About Dr. Jennifer Vickers Dr. Jennifer Vickers is a double board-certified dermatologist and dermatopathologist in Austin, Texas. She specializes in comprehensive skin, hair, and nail care, including general dermatology, pediatric dermatology, cosmetic dermatology, skin cancer screenings, mole evaluations, acne treatment, eczema management, psoriasis care, rashes, and autoimmune skin conditions.  She is also a principal dermatopathologist for Sanova Dermatology, reviewing skin biopsies to ensure accurate diagnoses, and serves as a co-investigator with the Austin Institute of Clinical Research. Learn more about Austin dermatologist Dr. Jennifer Vickers Follow Dr. Vickers on Instagram @jennifervickersmd About Dr. Lawrence Bass Innovator. Industry veteran. In-demand Park Avenue board certified plastic surgeon, Dr. Lawrence Bass is a true master of his craft, not only in the OR but as an industry pioneer in the development and evaluation of new aesthetic technologies. With locations in both Manhattan (on Park Avenue between 62nd and 63rd Streets) and in Great Neck, Long Island, Dr. Bass has earned his reputation as the plastic surgeon for the most discerning patients in NYC and beyond. To learn more, visit the Bass Plastic Surgery website or follow the team on Instagram @drbassnyc Subscribe to the Park Avenue Plastic Surgery Class newsletter to be notified of new episodes & receive exclusive invitations, offers, and information from Dr. Bass. 

Get My Brand Masterlist: https://drchristiangonzalez.com/best-brands-form-2-2/ → Shop all my verified, tested and preferred wellness products - includes most up to date brands: https://theswellscore.com/pages/drg Episode Description You started creatine, felt bloated, broke out, noticed your hair shedding — and then wondered if you were crazy. You weren't. But you were missing something important. Creatine is one of the most well-researched supplements in history. But almost all of that research was done on men. And when the wellness world rebranded it as a brain and energy supplement for women, nobody stopped to talk about hormones, cycle phases, gut tolerance, or the environment your body is actually in when you start taking it. Dr. G breaks down exactly what's happening — and who creatine is actually for. In this episode, you'll learn:  • Why creatine causes bloating, breakouts, and hair shedding in some women — and what it's actually telling you about your physiology  • The three groups of women when it comes to creatine: who benefits, who needs a modified approach, and who should skip it entirely for now  • What has to be in place before creatine can actually work — and why taking it on top of poor sleep, undereating, or overtraining almost always backfires If you've tried creatine and felt worse, or you're wondering if it's worth trying — this is the episode that gives you a real answer. Timestamps: 0:00 - Intro 1:00 - Why Creatine Crossed Over Into Women's Wellness (And What the Research Actually Says) 2:32 - How Creatine Actually Works in the Female Body 4:03 - What the Clinical Research on Women and Creatine Really Shows 5:28 - Bloating, Breakouts & Hair Shedding: What's Actually Causing It 7:04 - Why Your Physiology May Not Match What Creatine Is Asking of You 10:40 - The Three Groups: Who Should Take It, Who Should Be Careful, Who Should Skip It 12:33 - Final Word: Always Talk to a Professional First Learn more about your ad choices. Visit megaphone.fm/adchoices

Natalie Crawford, MD is board certified in both Obstetrics and Gynecology and Reproductive Endocrinology and Infertility and is co-founder of Fora Fertility, a boutique fertility practice in Austin, Texas. Dr. Crawford is CEO and co-founder of Pinnacle, a professional network for women in medicine. She completed her undergraduate at Auburn University obtaining a degree in Nutrition Science, Medical School at UTMB, OBGYN Residency at UTSW, and REI Fellowship at UNC, concurrently obtaining a Master of Science in Clinical Research. Dr. Crawford is a digital health educator on social media, YouTube, and hosts the podcast  “As a Woman” with over 6 million downloads. Her debut book, “The Fertility Formula”, will be released by Penguin Random House.   Follow Dr. Crawford on Instagram at @nataliecrawfordmd and check out her book, The Fertility Formula.   Related Episodes: Ep 155 - Dr. Marguerite Duane on FACTS about Fertility Ep 314 - The Fertility Crisis + Support for Couples with Ronit Menashe + Vida Delrahim   If you like this episode, please subscribe to Pursuing Health on iTunes and give it a rating or share your feedback on social media using the hashtag #PursuingHealth. I look forward to bringing you future episodes with inspiring individuals and ideas about health.   Disclaimer: This podcast is for general information only, and does not provide medical advice.  I recommend that you seek assistance from your personal physician for any health conditions or concerns.

I'm thrilled to connect with Dr. Natalie Crawford today. She's a double-board-certified fertility doctor and the author of The Fertility Formula. Unlike most other physicians, she blends lifestyle and functional medicine with science-based facts, aiming to help women conceive and understand their bodies. While this conversation may not feel fully aligned with the perimenopause and menopause transition, I encourage you to listen with an open mind to what Natalie shares about hormones. In our discussion, we explore fertility as a vital sign, the impact of infertility, and why one in six women experiences infertility. We break down ovarian reserve and the realities of aging. We also cover specific labs that can help assess ovarian reserve and overall health. We explain DOR and POI, the overlap between fertility and perimenopause, and why the ovaries can behave like a “cranky toddler” in perimenopause. Finally, we dive into the role of the gut microbiome in estrogen metabolism and inflammation, and discuss IVF, egg freezing, modern reproductive options, lifestyle influences, and a series of rapid-fire questions. Dr. Crawford's book, The Fertility Formula, is a must-read for women of all ages. It contains many valuable insights, and I love the way she blends an integrative approach with an allopathic approach for her patients. IN THIS EPISODE, YOU WILL LEARN: How fertility serves as a health marker that reflects a woman's hormonal, cellular, and metabolic health The role of inflammation in infertility Dr. Crawford clarifies ovarian reserve, highlighting the importance of understanding egg quality and quantity. Why AMH testing is the most informative first step for women concerned about their fertility Dr. Crawford outlines three factors that can cause missed or irregular periods. The importance of tracking ovulation and understanding the body's signals during perimenopause Inflammation and aging can disrupt chromosome alignment and impair embryo development. How poor estrogen clearance and gut microbiome imbalances disrupt brain-ovary signaling and ovulation timing The link between sleep deprivation and low sperm counts, and how stress and lack of muscle mass can drive insulin resistance and inflammation Why sleep, muscle mass, and stress reduction are all essential for fertility It's essential to approach fertility proactively, and to know how to do that. Bio: Natalie Crawford Natalie Crawford, MD, is board-certified in both Obstetrics and Gynecology and Reproductive Endocrinology and Infertility and is co-founder of Fora Fertility, a boutique fertility practice in Austin, Texas. Dr. Crawford is CEO and co-founder of Pinnacle, a professional network for women in medicine. She completed her undergraduate degree at Auburn University, obtaining a degree in Nutrition Science, Medical School at UTMB, OBGYN Residency at UTSW, and REI Fellowship at UNC, concurrently obtaining a Master of Science in Clinical Research. Dr. Crawford is a digital health educator on social media, YouTube, and hosts the podcast  “As a Woman” with over 6 million downloads. Her debut book, “The Fertility Formula”, will be released by Penguin Random House.  Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow. Cynthia's Menopause Gut Book is on presale now! Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line Connect with Dr. Natalie Crawford On her website On social media: @NatalieCrawfordMD Dr. Crawford's book, The Fertility Formula, is available here.